About the Company
Fusion Acquisition Corporation is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company was founded by and is led by CEO John James (who also stands behind the global fintech, BetaSmartz, as well as co-founding emerging opportunities investment company, Boka Group), and Chairman Jim Ross (senior advisor to State Street and former Chairman of State Street Global Advisors SPDR ETFs). Fusion is focusing on businesses with an enterprise value of approximately $750 million to $3 billion that are applying, providing or changing technology within the fintech or asset and wealth management sectors.
Employees
4400
Exchange
NEW YORK STOCK EXCHANGE INC.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FUSE News
What Fusion Pharmaceuticals (NASDAQ:FUSN) Acquisition Means for Investors
However, current investors in FUSN may want to stick around post-acquisition ... pending Fusion shareholder approval and necessary regulatory clearances. When a company is acquired or bought ...
Fusion Pharmaceuticals: Hold Rating Justified Amid Acquisition and Radiopharmaceutical Market Dynamics
The acquisition of Fusion Pharmaceuticals by AstraZeneca at a price of $21 per share, with an additional contingent value right, reflects a valuation that Zhi deems fair. The company’s Ac225 ...
What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals
The acquisition includes Fusion's late-stage ... This is a somewhat unsatisfying end of the story for IPO investors of Fusion as the company went public in June 2020 at $17 per share, but a ...
Behind the Scenes at The Arthouse Hotel: A Ben Ashkenazy Vision With A Fusion of Art, Hospitality, and Community Impact
Explore The Arthouse Hotel, a unique blend of art, hospitality, and community in Manhattan's Upper West Side. A Ben Ashkenazy ...
McMaster prof ‘still doing the same chores’ after company sells for $2.4 billion
AstraZeneca’s acquisition of Fusion Pharmaceuticals, announced March 19, marks the largest-ever sale for a ...
AstraZeneca to buy Canadian cancer specialist Fusion for $2.4bn
The company already has a collaboration with ... receive radiotherapy at some point during treatment, and the acquisition of Fusion furthers our ambition to transform this aspect of care with ...
FDA approves XStim spine fusion stimulator
Xstim announced today that it received premarket approval from the FDA for its Xstim spine fusion stimulator device.
Blue Laser Fusion Completes $37.5M Series Seed Funding Round With Investment From SoftBank Corp., Maezawa Fund, and Itochu Corporation
2024 / Blue Laser Fusion Inc. (BLF), a leading inertial fusion company, successfully closed its $37.5 million Series Seed funding round with investment from strategic partners SoftBank Corp., a ...
MPE Partners and Precision Pipeline Announce the Acquisition of SabCon Underground
MPE Partners ("MPE" or "Morgenthaler Private Equity"), along with its portfolio company Precision Pipeline ("Precision"), announced today the acquisition of SabCon Underground ("SabCon"). SabCon is a ...
Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca
Fusion Pharmaceuticals FUSN signed a definitive agreement with AstraZeneca AZN. Per the agreement terms, the pharma giant will acquire all outstanding shares of Fusion for $21 per share in cash ...
Loading the latest forecasts...